When it comes to diseases or ailments, symptoms can often overlap and could either mean something serious or something that is very much benign. The same could be said for diseases like cancer in whichever part of the body that has a tumor.
In terms of lung cancer, there is another symptom that should be noted that could be a sign of the presence of the disease in a person. Express reports that drooping eyes could be such a symptom. Lung cancer is one of the diseases that affect a lot of people in the United Kingdom, and though there is no cure for it yet, it is important to recognize the symptoms and make a visit to the doctor as soon as possible if the signs develop or get worse over time.
It is reported that some kinds of lung cancer can bring about Horner’s Syndrome, or more commonly known as drooping eyes. According to the American Cancer Society, some tumors in the lungs, the upper part specifically, are referred to as Pancoast tumors and are more likely “non-small cell lung cancer.”
This kind of tumor affects some nerves of the eye and a part of the face. One symptom of Horner’s Syndrome is one eyelid drooping or the weakness of one eyelid. Another symptom found in the eye is a smaller pupil.
While there is no exact cause when it comes to lung cancer, there are factors that could determine whether a person has a big risk of developing the disease or not. There are factors beyond a person’s control which could put them at a risk, but lifestyle plays a big part in it as well. The most popular known factor is smoking, and heavy smokers have a higher risk of developing this cancer. However, it can be controlled by quitting the habit.
Simply put, the more you smoke, the more you are at risk for lung cancer.
But unfortunately, even non-smokers can develop lung cancer, popularly through inhaling the secondhand smoke coming from smokers. Other factors would be exposure to other carcinogens and asbestos as well as radon gas.


Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 



